STAT+: Up and down the ladder: The latest comings and goings

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

By SilvermanOct 2, 2026

Score█████░░░░░5.0

VerdictCompetent work. Briefs at most.

Summary from the source

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

Ed Silverman

Heuristic review

Dimension	Level	Weight	What that level means
Leverage	██░░░ 2	15%	Reusable within one subfield (a technique, dataset, or protocol a few groups will adopt).
Magnitude	██░░░ 2	20%	Solid incremental gain on a meaningful problem.
Evidence	███░░ 3	20%	Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.
Novelty	██░░░ 2	10%	A new combination of known ideas.
Trajectory	██░░░ 2	10%	Some room to improve with obvious engineering.
Stakes	██░░░ 2	25%	Benefits a professional community (practitioners, clinicians, engineers).

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: verification (error bars).

rank-2026-09-29

Score█████░░░░░5.0

Score = 10 × (50% × adjusted merit / 10 + 25% × attention + 25% × freshness)

Merit: 4.4 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 4.1 / 10; Shrunk toward the desk prior by editor confidence (30%).
Attention: 28%; Citations, upvotes, points, mentions.
Freshness: 90%; Half-life decay since publication.

No attention signals recorded yet.